Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

DNA vaccination against bcr-abl-positive cells in mice

V. Lučanský, E. Sobotková, R. Tachezy, M. Dušková, V. Vonka

. 2009 ; 35 (4) : 941-951.

Jazyk angličtina Země Řecko

Typ dokumentu práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc11022316

Grantová podpora
NR9075 MZ0 CEP - Centrální evidence projektů

Digitální knihovna NLK
Plný text - Část
Zdroj

E-zdroje NLK

Free Medical Journals od 2006 do Před 1 rokem

A series of DNA vaccines based on the bcr-abl fusion gene were developed and tested in mice. Two mouse (BALB/c) bcr-abl-transformed cell lines, B210 and 12B1, which both expressed p210bcr-abl and were oncogenic for syngeneic animals but differed in some other respects, were used as a model system. In the first series of experiments, plasmids carrying either the complete bcr-abl fusion gene or a fragment thereof coding for a 25-amino acid-long junction zone (bcr-abl25aa) linked with genes coding for a variety of immunostimulatory factors were used as the DNA vaccines. A plasmid carrying the complete bcr-abl gene was capable of inducing protection against challenge with either B210 or 12B1 cells. However, the DNA vaccines based on the gene fragment coding for p25aabcr-abl did not induce significant protection. To localize the immunizing epitopes on the p210bcr-abl protein, the whole fusion gene was split into nine overlapping fragments and these, individually or in various combinations, were used for immunization. Although none of the vaccines based on any single fragment provided potent protection, some combinations of these fragment-based vaccines were capable of eliciting protection comparable to that seen after immunization with the whole-gene vaccine. Surprisingly, a mixture of six fragment-vaccines was more immunogenic than the complete set of fragment DNA vaccines. To analyze this phenomenon, the three fragments missing from the hexavaccine were either individually or in various combinations mixed with the hexavaccine. The results obtained suggested that the product of the fragment coding for 197 amino acids forming the N-terminal of the BCR protein was involved in the decreased immunogenicity. However, further experiments are needed to clarify the point. Additional experiments revealed that all the important epitopes were located in the ABL portion of the p210bcr-abl protein. The livers, spleens and bone marrows of the successfully immunized animals were tested for the presence of bcr-abl-positive cells by RT-PCR. The results were negative, this suggesting that these animals were free of any residual disease.

000      
04059naa 2200493 a 4500
001      
bmc11022316
003      
CZ-PrNML
005      
20140224140422.0
008      
110729s2009 gr e Eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Lučanský, Vincent. $7 xx0306234
245    10
$a DNA vaccination against bcr-abl-positive cells in mice / $c V. Lučanský, E. Sobotková, R. Tachezy, M. Dušková, V. Vonka
314    __
$a Department of Experimental Virology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
520    9_
$a A series of DNA vaccines based on the bcr-abl fusion gene were developed and tested in mice. Two mouse (BALB/c) bcr-abl-transformed cell lines, B210 and 12B1, which both expressed p210bcr-abl and were oncogenic for syngeneic animals but differed in some other respects, were used as a model system. In the first series of experiments, plasmids carrying either the complete bcr-abl fusion gene or a fragment thereof coding for a 25-amino acid-long junction zone (bcr-abl25aa) linked with genes coding for a variety of immunostimulatory factors were used as the DNA vaccines. A plasmid carrying the complete bcr-abl gene was capable of inducing protection against challenge with either B210 or 12B1 cells. However, the DNA vaccines based on the gene fragment coding for p25aabcr-abl did not induce significant protection. To localize the immunizing epitopes on the p210bcr-abl protein, the whole fusion gene was split into nine overlapping fragments and these, individually or in various combinations, were used for immunization. Although none of the vaccines based on any single fragment provided potent protection, some combinations of these fragment-based vaccines were capable of eliciting protection comparable to that seen after immunization with the whole-gene vaccine. Surprisingly, a mixture of six fragment-vaccines was more immunogenic than the complete set of fragment DNA vaccines. To analyze this phenomenon, the three fragments missing from the hexavaccine were either individually or in various combinations mixed with the hexavaccine. The results obtained suggested that the product of the fragment coding for 197 amino acids forming the N-terminal of the BCR protein was involved in the decreased immunogenicity. However, further experiments are needed to clarify the point. Additional experiments revealed that all the important epitopes were located in the ABL portion of the p210bcr-abl protein. The livers, spleens and bone marrows of the successfully immunized animals were tested for the presence of bcr-abl-positive cells by RT-PCR. The results were negative, this suggesting that these animals were free of any residual disease.
590    __
$a bohemika - dle Pubmed
650    _2
$a zvířata $7 D000818
650    _2
$a protinádorové vakcíny $x genetika $x imunologie $7 D019496
650    _2
$a mapování epitopu $7 D018604
650    _2
$a bcr-abl fúzové proteiny $x genetika $x imunologie $7 D016044
650    _2
$a HL-60 buňky $7 D018922
650    _2
$a lidé $7 D006801
650    _2
$a imunizace $7 D007114
650    _2
$a chronická myeloidní leukemie $x genetika $x imunologie $x patologie $x prevence a kontrola $7 D015464
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední BALB C $7 D008807
650    _2
$a peptidové fragmenty $x imunologie $7 D010446
650    _2
$a časové faktory $7 D013997
650    _2
$a transfekce $7 D014162
650    _2
$a DNA vakcíny $x genetika $x imunologie $7 D019444
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Sobotková, Eva $7 xx0103776
700    1_
$a Tachezy, Ruth $7 xx0060363
700    1_
$a Dušková, Martina $7 xx0127833
700    1_
$a Vonka, Vladimír, $d 1930- $7 jk01150642
773    0_
$t International Journal of Oncology $w MED00002350 $g Roč. 35, č. 4 (2009), s. 941-951
910    __
$a ABA008 $b x $y 2 $z 0
990    __
$a 20110801130719 $b ABA008
991    __
$a 20140224141233 $b ABA008
999    __
$a ok $b bmc $g 881709 $s 732235
BAS    __
$a 3
BMC    __
$a 2009 $x MED00002350 $b 35 $c 4 $d 941-951 $m International journal of oncology $n Int J Oncol
GRA    __
$a NR9075 $p MZ0
LZP    __
$a 2011-4B09/jvme